Patents by Inventor Kim Campbell

Kim Campbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11924066
    Abstract: Systems and methods for ticket-based provisioning of cloud infrastructure from one or more cloud providers to build one or more computing workspaces of an enterprise. A provisioning platform provides a module catalog having one or more infrastructure-as-code (IAC) modules, each including code that is executable to provision cloud computing resources for the cloud infrastructure from the cloud providers to build the computing workspaces of the enterprise. A service catalog has one or more electronic entries mapped to and corresponding with the IAC modules of the module catalog. The service catalog receives one or more tickets that each specify at least one of the electronic entries in the service catalog, to bind each specified electronic entry with a corresponding IAC module, causing the provisioning platform to instantiate on the more cloud providers the computing resources for the cloud infrastructure corresponding to the ticket.
    Type: Grant
    Filed: August 15, 2022
    Date of Patent: March 5, 2024
    Assignee: HashiCorp
    Inventors: Paul Welch, Kim Ngo, Justin Campbell, Greg Hoin, Lauren Rother
  • Publication number: 20210388318
    Abstract: Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004).
    Type: Application
    Filed: August 26, 2021
    Publication date: December 16, 2021
    Inventors: David Peritt, Kim Campbell, Amy Krutsick
  • Patent number: 11124767
    Abstract: Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004).
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: September 21, 2021
    Assignee: Mallinckrodt Pharmaceuticals Ireland Limited
    Inventors: David Peritt, Kim Campbell, Amy Krutsick
  • Publication number: 20190055516
    Abstract: Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004).
    Type: Application
    Filed: October 19, 2018
    Publication date: February 21, 2019
    Inventors: David Peritt, Kim Campbell, Amy Krutsick
  • Patent number: 10138464
    Abstract: Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004).
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: November 27, 2018
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: David Peritt, Kim Campbell, Amy Krutsick
  • Publication number: 20160046909
    Abstract: Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004).
    Type: Application
    Filed: September 23, 2015
    Publication date: February 18, 2016
    Inventors: David Peritt, Kim Campbell, Amy Krutsick
  • Patent number: 9169461
    Abstract: Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004).
    Type: Grant
    Filed: November 2, 2006
    Date of Patent: October 27, 2015
    Assignee: Therakos, Inc.
    Inventors: David Peritt, Kim Campbell, Amy Krutsick
  • Publication number: 20080267934
    Abstract: Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004).
    Type: Application
    Filed: November 2, 2006
    Publication date: October 30, 2008
    Inventors: David Peritt, Kim Campbell, Amy Krutsick
  • Publication number: 20070098686
    Abstract: The present invention provides a method of generating T cells with regulatory activity by incubating leukocytes with autologous apoptotic peripheral blood mononuclear cells.
    Type: Application
    Filed: November 2, 2006
    Publication date: May 3, 2007
    Inventors: David Peritt, Kim Campbell, Amy Krutsick
  • Publication number: 20050163778
    Abstract: Methods of treating an autoimmune disease, an atopic disease, transplantion rejection or GVHD or ameliorating one or more symptoms thereof involves the use of a combination therapy. The therapy involves administering to a subject an extracorporeal photopheresis and a TNF ? antagonist.
    Type: Application
    Filed: December 21, 2004
    Publication date: July 28, 2005
    Inventors: David Peritt, Kim Campbell, Jill Giles-Komar, Gregory Harriman